Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Investing.com - Piper Sandler has lowered its price target on CAMP4 Therapeutics Corp (NASDAQ:CAMP) to $12.00 from $18.00 while maintaining an Overweight rating on the stock. The company’s shares, currently trading at $3.25, have shown significant momentum with a 97% return over the last week, though still down nearly 70% over the past year. According to InvestingPro data, the stock is trading near its Fair Value.
The research firm noted that CAMP4 recently raised $50 million, bringing its pro forma cash to approximately $86.1 million, which should fund operations into 2027. Participating investors have agreed to purchase an additional $50 million upon acceptance of the Clinical Trial Application (CTA) for CPS-SYNGAP-01, expected in the second half of 2026. InvestingPro analysis shows the company holds more cash than debt on its balance sheet, though it’s quickly burning through cash reserves with a current ratio of 5.6x.
At the American Society of Gene & Cell Therapy (ASGCT) meeting, CAMP4 presented data showing that CMP-SYNGAP-01 restored SYGNAP1 protein levels across brain regions in mice and non-human primates, while reversing behavioral and cognitive deficits in models of SYNGAP-related disorders. The company plans to initiate a Phase I/II study of CMP-SYNGAP-01 in the second half of 2026.
Interim Phase I single ascending dose (SAD) data demonstrated that CMP-CPS-001 was safe and well-tolerated. CAMP4 expects to report Phase I safety, pharmacokinetic, and biomarker data on all four SAD cohorts and the first three multiple ascending dose (MAD) cohorts in the fourth quarter of 2025.
Piper Sandler’s price target reduction reflects increased value for CMP-SYNGAP-01, reduced value for CMP-CPS-001, and dilution effects from the recent financing round. The broader analyst consensus remains strongly bullish, with InvestingPro showing price targets ranging from $7.00 to $21.65. Subscribers can access 11 additional exclusive ProTips and comprehensive financial metrics for CAMP4 Therapeutics.
In other recent news, CAMP4 Therapeutics Corporation announced a significant development involving a $100 million private placement. The company has already secured $50 million through the sale of common stock and pre-funded warrants, with the potential to receive an additional $50 million upon meeting specific milestones. These milestones include regulatory clearance for a Phase 1/2 clinical trial for their SYNGAP1 development candidate, anticipated to commence in the latter half of 2026. Meanwhile, Sequans Communications S.A. has appointed Jason W. Cohenour to its Board of Directors. Cohenour, with over 30 years of executive leadership experience, previously served as President, CEO, and Director of Sierra Wireless, Inc. His tenure at Sierra Wireless was marked by strategic transformations that significantly increased the company’s revenue and established it as a key player in the Internet of Things market. These recent developments reflect ongoing strategic and financial activities within both CAMP4 Therapeutics and Sequans Communications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.